# The Effect of Semaglutide on Cardiovascular Markers and Liver Function

> **NCT06301191** · — · UNKNOWN · sponsor: **Attikon Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Diabetes Type 2

## Interventions

- **DRUG:** Semaglutide, 1.0 mg/mL
- **DRUG:** Dipeptidyl Peptidase 4 inhibitor

## Key facts

- **NCT ID:** NCT06301191
- **Lead sponsor:** Attikon Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-01
- **Primary completion:** 2023-03-01
- **Final completion:** 2024-05-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06301191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06301191, "The Effect of Semaglutide on Cardiovascular Markers and Liver Function". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06301191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*